Traditional Chinese medicine preparation for treating gynecological pelvic inflammation and preparation method thereof

Through traditional Chinese medicine preparations composed of Chinese medicines such as Chinese yam, the problem of unsatisfactory and high cost of pelvic inflammatory disease treatment in the existing technology is solved, and the effects of clearing heat and dampness, promoting blood circulation and unblocking the kidneys and replenishing qi are achieved, which significantly improves dampness, heat and blood stasis and stasis, and significantly improves the dampness, heat and blood stasis dysfunction. Symptoms of pelvic inflammatory disease and sagittal disease.

CN119033887AActive Publication Date: 2024-11-29ZHONGSHAN HUANGPU PEOPLES HOSPITAL
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411208577.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-30
Publication Date
2024-11-29
Estimated Expiration
2044-08-30

AI Technical Summary

Technical Problem

Among the existing methods for treating pelvic inflammatory disease, antibiotics are not effective and have high drug resistance. Laparoscopic surgery is high and individual differences are large. Traditional Chinese medicine believes that dampness, heat, and blood stasis are the main pathogenesis, but there is a lack of effective Chinese medicine preparations to clear heat and dampness. Promote blood circulation and remove blood stasis, promote qi and relieve pain.

Method used

Chinese medicine preparations composed of Chinese medicines such as wild yam, holly lemon, honeysuckle vine, dandelion, plantain, motherwort, Lulutong, red peony, wine Chuanxiong, vinegar, golden cherry root, golden retriever dog spine, five-finger hair peach, etc., are boiled and The steps of filtration are prepared into oral liquid, tablets, granules or capsules, combined with sodium benzoate as an auxiliary material, and are used to treat gynecological pelvic inflammatory disease.

Benefits of technology

This traditional Chinese medicine preparation can effectively clear heat and dampness, promote blood circulation and unblock meridians, nourish the kidney and qi, regulate menstruation and stop the belt, significantly improve damp heat and blood stasis and pelvic inflammatory disease, have good clinical efficacy, and the materials are simple and cheap.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005019728820000101
    Figure BDA0005019728820000101
  • Figure BDA0005019728820000111
    Figure BDA0005019728820000111
  • Figure BDA0005019728820000114
    Figure BDA0005019728820000114
Patent Text Reader

Abstract

The invention belongs to the field of medicine, and particularly discloses a traditional Chinese medicine preparation for treating gynecological pelvic inflammation. The traditional Chinese medicine preparation is prepared from the following components in parts by mass: 10-16 parts of rhizoma smilacis glabrae, 5-7 parts of pubescent holly root, 5-7 parts of honeysuckle stem, 5-8 parts of dandelion, 5-7 parts of plantain herb, 5-7 parts of motherwort, 5-7 parts of beautiful sweetgum fruit, 7-11 parts of red paeony root, 5-8 parts of wine-processed ligusticum wallichii, 5.5-6.5 parts of vinegar-processed rhizoma cyperi, 7-10 parts of cherokee rose root, 6-10 parts of cibotium barometz and 11-15 parts of radix fici simplicissimae. The traditional Chinese medicine preparation is wide in medicinal material source and low in price, can clear away heat and eliminate dampness, promote blood circulation to remove blood stasis and promote qi circulation to relieve pain, and has a good treatment effect on pelvic inflammation. The invention further discloses a preparation method of the traditional Chinese medicine preparation for treating gynecological pelvic inflammation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medicine, and specifically relates to a traditional Chinese medicine preparation for treating gynecological pelvic inflammatory disease and a preparation method thereof. Background Art

[0002] Pelvic inflammatory disease (PID) is a common infectious disease of the female upper reproductive tract and its surrounding tissues. Its occurrence is related to sexually transmitted infections such as Chlamydia trachomatis and Neisseria gonorrhoeae. According to traditional Chinese medicine, it is classified as "abdominal pain in women", "leucorrhea", "mass masses", "irregular menstruation", etc. The causes are mainly damp-heat stasis, qi stagnation and blood stasis, spleen and kidney deficiency and blood stasis, and spleen deficiency and dampness stasis. It is a common and frequently occurring disease in women of childbearing age. The clinical manifestations are lower abdominal pain, abdominal distension, increased leucorrhea, etc. If not treated in time, it can lead to a series of sequelae, resulting in menstrual disorders, chronic pelvic pain, and even infertility, which seriously affects the reproductive health and quality of life of patients.

[0003] At present, Western medicine mainly uses antibiotics or laparoscopic surgery for symptomatic treatment of pelvic inflammatory disease, but only most patients use sensitive antibiotics, and a small number of patients use antibiotics to which the pathogens are resistant. The incidence of drug resistance is high and the therapeutic effect is not ideal. The treatment efficiency and pelvic mass clearance rate of laparoscopic surgery are higher than those of antibiotics, but the treatment cost is high, the economic pressure is great, the individual differences after surgery are large, and the prognosis of some patients is poor. It may affect the secretion of reproductive hormones, reduce ovarian reserve capacity, and low sexual function.

[0004] According to traditional Chinese medicine, the etiology of this disease can be summarized as dampness, heat, stasis, cold, and deficiency, with dampness and heat as the main cause and blood stasis as the basic pathogenesis. Dampness and heat toxic evils remain in the Chong, Ren, and Baogong, and fight with qi and blood, forming stasis, thus leading to this disease. Traditional Chinese medicine preparations have few side effects and significant efficacy, so it is particularly important to provide a traditional Chinese medicine preparation that can treat gynecological pelvic inflammatory disease. Summary of the invention

[0005] The purpose of the present invention is to provide a Chinese medicine preparation for treating gynecological pelvic inflammatory disease. The Chinese medicine preparation has a wide range of medicinal materials and is low in price. It can clear away heat and dampness, promote blood circulation and remove blood stasis, promote qi and relieve pain, and has a good therapeutic effect on pelvic inflammatory disease.

[0006] In order to achieve the above object, the present invention adopts the following technical solutions:

[0007] A traditional Chinese medicine preparation for treating gynecological pelvic inflammatory disease is prepared from the following components in parts by weight:

[0008] 10-16 parts of Smilax glabra, 5-7 parts of Ilex tomentosa, 5-7 parts of Honeysuckle vine, 5-8 parts of Taraxacum, 5-7 parts of Plantain, 5-7 parts of Leonurus japonicus, 5-7 parts of Fructus Smilacis Glabrae, 7-11 parts of Red Peony Root, 5-8 parts of Ligusticum chuanxiong, 5.5-6.5 parts of Cyperus rotundus with vinegar, 7-10 parts of Cherry Blossom Root, 6-10 parts of Cibotium barometz, and 11-15 parts of Prunus mume.

[0009] The further described Chinese medicine preparation for treating gynecological pelvic inflammatory disease is prepared from the following components in parts by weight:

[0010] 13 parts of Rhizoma Smilacis Glabrae, 6 parts of Ilex Tomentosa, 6 parts of Caulis Honeysuckle, 6 parts of Herba Taraxaci, 6 parts of Herba Plantaine, 6 parts of Herba Leonuri, 6 parts of Fructus Liquidambaridis, 9 parts of Radix Paeoniae Rubra, 6 parts of Rhizoma Chuanxiong with wine, 6 parts of Rhizoma Cyperi with vinegar, 9 parts of Radix Chrysanthemi Laevigatae, 8 parts of Cibotium Caninae, and 13 parts of Prunus Armeniacae.

[0011] The dosage form of the traditional Chinese medicine preparation is one of oral liquid, tablet, granule and capsule.

[0012] The present invention also provides a method for preparing the Chinese medicine preparation for treating gynecological pelvic inflammatory disease, comprising the following steps:

[0013] S1 Weigh each Chinese medicine component in proportion and mix them together, add 4 to 8 times of drinking water to soak for 30 to 50 minutes, heat to 100°C and keep it slightly boiling for 30 to 60 minutes;

[0014] S2 filters the cooked medicinal liquid in S1 to obtain the filtrate for later use; adds 4 to 6 times of drinking water to the filtered medicinal residue, and repeats the above heating and filtering operations 1 to 2 times;

[0015] S3 combines several filtrates, heats them in a concentrator and concentrates them into a concentrated liquid or thick paste, and then sterilizes them to prepare the desired dosage form.

[0016] In the present invention, when the dosage form prepared is an oral liquid, the filtrate needs to be heated and concentrated into a concentrated liquid in a concentrator, and a proper amount of pharmaceutical excipients is added, stirred evenly, and bottled according to the required specifications.

[0017] The general bottling specification is 100ml / bottle, which is equivalent to 165g of Chinese medicine slices. The oral dosage is one bottle per day, twice a day, and one bottle is taken twice.

[0018] The pharmaceutical excipient is sodium benzoate, and the added amount of the sodium benzoate is 0.1-0.2% of the mass of the concentrated solution.

[0019] When the dosage form to be prepared is tablets, granules or capsules, the filtrate needs to be heated in a concentrator and concentrated into a thick paste, dried, crushed, sieved, added with an appropriate amount of pharmaceutical excipients, granulated or not granulated, and filled into capsules to obtain capsules; or added with an appropriate amount of pharmaceutical excipients, granulated or not granulated, pressed into tablets to obtain tablets; or added with an appropriate amount of pharmaceutical excipients to form granules to obtain granules.

[0020] Formula Pharmacology: In the formula, Smilax glabra and Ilex podophylla are the main drugs, which can clear away heat, detoxify and eliminate dampness; Taraxacum officinale, Honeysuckle (Lonicera japonica), and Plantago are the assistant drugs, which can enhance the main drugs' efficacy of clearing away heat, detoxifying and eliminating dampness; Leonurus japonicus, Rhizoma Clematis, Cyperus rotundus, Paeonia lactiflora, and Rhizoma Chuanxiong have the functions of promoting blood circulation and removing blood stasis, regulating qi and relieving pain, and are combined with Rhizoma Chrysantha, Cibotium barometz, and Prunus mume to nourish the spleen and kidney, to consolidate the innate and acquired foundation, and as auxiliary drugs, to clear away heat without hurting the body, and to strengthen the body to drive away evil. The whole formula is reasonably compatible, and the drugs are used together to play the functions of clearing away heat and removing dampness, promoting blood circulation and unblocking collaterals, nourishing the kidney and replenishing qi, regulating menstruation and stopping leukorrhea, and have long had ideal clinical efficacy.

[0021] Clinical Application:

[0022] 1. Abdominal pain in women

[0023] It is caused by damp-heat blocking the Chong and Ren meridians and poor blood circulation in the uterine vessels. Symptoms include lower abdominal pain that is resistant to pressure, lumbar and sacral distension and pain, increased vaginal discharge that is yellow and thick with an odor, or accompanied by fluctuating low fever, chest tightness and irritability, bitter taste in the mouth and dry throat, poor appetite, yellow and scanty urine, red tongue, yellow and greasy tongue coating, and a stringy and rapid pulse. Acute and chronic pelvic inflammatory disease with the above symptoms.

[0024] 2. Leucorrhea

[0025] It is caused by damp-heat obstruction, which damages the Ren and Dai meridians. Symptoms include increased vaginal discharge, which is yellow and thick with an odor, or lower abdominal pain, or vaginal itching, chest tightness and irritability, bitter taste in the mouth and dry throat, poor appetite, yellow and scanty urine, red tongue, yellow and greasy tongue coating, and a stringy and rapid pulse. The above symptoms are seen in patients with acute or chronic pelvic inflammatory disease.

[0026] Compared with the prior art, the present invention has the following beneficial effects:

[0027] The Chinese medicine preparation for treating gynecological pelvic inflammatory disease of the present invention can clear away heat and dampness, promote blood circulation and dredge collaterals, tonify the kidney and invigorate qi, regulate menstruation and stop leukorrhea, and is mainly used to treat pelvic inflammatory diseases of damp-heat stasis type, leukorrhea caused by damp-heat stasis, and acute and chronic pelvic inflammatory disease. The raw materials of the medicinal materials of the present invention are simple and inexpensive, and have a good therapeutic effect. DETAILED DESCRIPTION

[0028] The present invention is further illustrated below by way of examples.

[0029] 1. Preparation of Chinese medicine preparations for the treatment of gynecological pelvic inflammatory disease

[0030] Example 1

[0031] The Chinese medicine preparation for treating gynecological pelvic inflammatory disease of this embodiment is prepared from the following components in parts by weight:

[0032] 13 parts of Rhizoma Smilacis Glabrae, 6 parts of Ilex Tomentosa, 6 parts of Caulis Honeysuckle, 6 parts of Herba Taraxaci, 6 parts of Herba Plantaine, 6 parts of Herba Leonuri, 6 parts of Fructus Liquidambaridis, 9 parts of Radix Paeoniae Rubra, 6 parts of Rhizoma Chuanxiong with wine, 6 parts of Rhizoma Cyperi with vinegar, 9 parts of Radix Chrysanthemi Laevigatae, 8 parts of Cibotium Caninae, and 13 parts of Prunus Armeniacae.

[0033] The preparation method of the Chinese medicine preparation for treating gynecological pelvic inflammatory disease in this embodiment is as follows:

[0034] S1 Mix the above Chinese medicine components according to the proportion, add 5 times drinking water to soak for 30 minutes, heat to 100℃ and keep it slightly boiling for 40 minutes;

[0035] S2 filters the cooked medicinal liquid in S1 to obtain the filtrate for later use; add 5 times of drinking water to the filtered medicinal residue, and repeat the above heating and filtering operations once;

[0036] S3: Combine the filtrates from the first and second times, heat and concentrate them into a concentrated solution in a concentrator, add 0.1-0.2% of the mass of the concentrated solution of sodium benzoate, stir evenly, and package in 100 ml / bottle specifications.

[0037] Example 2

[0038] The Chinese medicine preparation for treating gynecological pelvic inflammatory disease of this embodiment is prepared from the following components in parts by weight:

[0039] 13 parts of Rhizoma Smilacis Glabrae, 5 parts of Ilex Tomentosa, 7 parts of Caulis Honeysuckle, 8 parts of Herba Taraxaci, 7 parts of Herba Plantaine, 7 parts of Herba Leonuri, 6 parts of Fructus Liquidambaridis, 7 parts of Radix Paeoniae Rubra, 5 parts of Rhizoma Chuanxiong with wine, 6 parts of Rhizoma Cyperi with vinegar, 7 parts of Radix Chrysanthemi Laevigatae, 6 parts of Cibotium barometz, and 15 parts of Prunus mume.

[0040] The preparation method of the Chinese medicine preparation for treating gynecological pelvic inflammatory disease in this embodiment is as follows:

[0041] S1 Mix the above Chinese medicine components according to the proportion, add 6 times drinking water to soak for 40 minutes, heat to 100℃ and keep it slightly boiling for 50 minutes;

[0042] S2 filters the cooked medicinal liquid in S1 to obtain the filtrate for later use; add 6 times of drinking water to the filtered medicinal residue, and repeat the above heating and filtering operations twice;

[0043] S3: Combine the filtrates from the three times, heat and concentrate into a thick paste in a concentrator, add appropriate amount of pharmaceutical excipients, stir, granulate, dry, and granulate to obtain granules.

[0044] Example 3

[0045] The Chinese medicine preparation for treating gynecological pelvic inflammatory disease of this embodiment is prepared from the following components in parts by weight:

[0046] 16 parts of Rhizoma Smilacis Glabrae, 7 parts of Ilex Tomentosa, 5 parts of Caulis Honeysuckle, 5 parts of Herba Taraxaci, 7 parts of Herba Plantaine, 6 parts of Herba Leonuri, 7 parts of Fructus Liquidambaridis, 7 parts of Radix Paeoniae Rubra, 8 parts of Rhizoma Chuanxiong with wine, 6.5 parts of Rhizoma Cyperi with vinegar, 10 parts of Radix Chrysanthemi Laevigatae, 10 parts of Cibotium Chinensis, and 11 parts of Prunus Armeniacae Indica.

[0047] The preparation method of the Chinese medicine preparation for treating gynecological pelvic inflammatory disease in this embodiment is as follows:

[0048] S1: Mix the above Chinese medicine components according to the proportion, add 8 times drinking water to soak for 30 minutes, heat to 100℃ and keep it slightly boiling for 60 minutes;

[0049] S2 filters the cooked medicinal liquid in S1 to obtain the filtrate for later use; add 5 times of drinking water to the filtered medicinal residue, and repeat the above heating and filtering operations twice;

[0050] S3: Combine the filtrates from the three times, heat and concentrate in a concentrator to form a thick paste, dry, grind into fine powder, granulate and fill into capsules to obtain capsules.

[0051] Example 4

[0052] The Chinese medicine preparation for treating gynecological pelvic inflammatory disease of this embodiment is prepared from the following components in parts by weight:

[0053] 10 parts of Rhizoma Smilacis Glabrae, 5 parts of Ilex Tomentosa, 6 parts of Caulis Honeysuckle, 8 parts of Herba Taraxaci, 7 parts of Herba Plantaine, 5 parts of Herba Leonuri, 6 parts of Fructus Liquidambaridis, 11 parts of Radix Paeoniae Rubra, 5 parts of Rhizoma Chuanxiong with Wine, 5.5 parts of Rhizoma Cyperi with Vinegar, 7 parts of Radix Chrysanthemi Laevigatae, 8 parts of Cibotium Caninae, and 14 parts of Prunus Armeniacae.

[0054] The preparation method of the Chinese medicine preparation for treating gynecological pelvic inflammatory disease in this embodiment is as follows:

[0055] S1 Mix the above Chinese medicine components according to the proportion, add 5 times drinking water to soak for 40 minutes, heat to 100℃ and keep it slightly boiling for 30 minutes;

[0056] S2 filters the cooked medicinal liquid in S1 to obtain the filtrate for later use; add 6 times of drinking water to the filtered medicinal residue, and repeat the above heating and filtering operations once;

[0057] S3: Combine the filtrates from the first and second times, heat and concentrate into a thick paste in a concentrator, dry, grind into fine powder, add appropriate amount of pharmaceutical excipients and press into tablets to obtain tablets.

[0058] 2. Animal Experiments

[0059] 1. Animals and commonly used materials:

[0060] 1.1 Animals:

[0061] Female non-pregnant SD rats, SPF grade, about 9 weeks old, weighing (220±20)g. The living environment temperature was controlled within the range of 25±2℃, humidity: 60%±10%; water and food were not restricted.

[0062] 1.2 Commonly used materials:

[0063] 0.9% sodium chloride injection (Hunan Kelun Pharmaceutical Co., Ltd., batch number: XY2242); the oral liquid of the traditional Chinese medicine preparation for the treatment of gynecological pelvic inflammatory disease prepared in Example 1 is called "Jinyin Yimu Ning Mixture" for easy distinction (Huangpu People's Hospital, Zhongshan City, Guangdong Province, batch number: 20230206); Penyanjing Granules (Kunming Jida Pharmaceutical Co., Ltd., batch number: 2312081; 10g×8 bags); 10% chloral hydrate solution (superior pure GR, Taizhou Yunke Biotechnology, batch number 2023-08).

[0064] 2. Anti-inflammatory and immunomodulatory effects of Jinyin Yimu Ning mixture on PID model rats

[0065] 2.1 Reagents:

[0066] TGF-β1 kit (Wuhan Sanying, 22308); Smad2 (Wuhan Sanying, 67343); Smad3 (Wuhan Sanying, 66516); DAB colorimetric kit (Wuhan Sanying, B500031); medical gelatin (Guangzhou Kuaikang Medical Instrument Co., Ltd., 0689-2013); interleukin-2 (IL-2), interleukin-6 (IL-6), and tumor scurvy factor (TNF-α) were purchased from Shanghai Qiaoyu Biotechnology Co., Ltd.; 4% paraformaldehyde fixative (Leibokang, LA0427). Escherichia coli and Staphylococcus aureus were from the Microbiology Laboratory of Guangdong Pharmaceutical University.

[0067] 2.2 Instruments:

[0068] Multifunctional image analysis software (Olympus); cell density meter (DEN-1, UK); microplate reader (varioskanLUX, Thermo Fisher); microscope digital camera (DP80, Japan); research upright fluorescence microscope (Olympus BX53); fluorescence quantitative PCR instrument (Bio-Rad CFX96Touch); homogenizer (APV-2000); high-efficiency centrifuge (Beckman Coulter, USA, Avanti J-26S XP); gel imaging system (Bio-Rad GelDoc Go).

[0069] 2.3 Experimental methods

[0070] 2.3.1 Preparation of animal models and grouping

[0071] Prepare 3 × 108 CFU / mL mixed bacterial solution (Escherichia coli: Staphylococcus aureus = 2:1) for later use. Sterilized gelatin sponge was made into 6mm×6mm size to fully absorb the mixed bacterial solution. Anesthetized rats were anesthetized by intraperitoneal injection of 10% chloral hydrate solution at 5mL / kg (fasting for 12h before anesthesia). An incision of about 1cm was made along the midline of the lower abdomen of the anesthetized rats to expose the uterus. A sterile syringe needle was used to push and pull the uterine opening back and forth 5 times to cause mechanical damage. The gelatin sponge containing bacterial solution was placed at the intersection of the rat uterus and fallopian tube, and one piece was placed on each side. It was sutured and disinfected. The blank group rats were not specially treated, and the sham operation group was placed with gelatin sponge without bacterial solution in the same way. The modeling was checked after 10 days.

[0072] Ten rats were randomly selected as the blank group and ten rats as the sham operation group. The model control group, Penyanjing granule group (13.95 g / kg·d -1 ), low-dose group of Jinyin Yimu Ning mixture (3.24 g / kg·d -1 ), medium dose group (6.48 g / kg·d -1 ), high-dose group (12.96 g / kg·d -1 ) (calculated based on the dosage reference standard of 100 mL per day for a 60 kg adult) 5 groups, 10 in each group.

[0073] 2.3.2 Drug administration

[0074] The mice were given 10 mL / kg ig (orally), once a day, for 30 consecutive days. The blank group and the sham operation group were given the same dose of normal saline.

[0075] 2.3.3 Sample collection and processing

[0076] Each group of rats was anesthetized by intraperitoneal injection of 10% chloral hydrate solution at 5 mL / kg (fasting for 12 hours before anesthesia). After anesthesia, blood was collected from the abdominal aorta, and serum was collected by centrifugation at 3000 r / min for 10 minutes. The serum TNF-α, IL-6, IL-2, and IL-10 levels were detected according to the operating instructions of the ELISA kit. The pelvic and abdominal cavity, uterus, and bilateral fallopian tubes were observed after autopsy by cervical dislocation. The uterine tissue mass was weighed and the uterine coefficient was calculated. The uterine coefficient = uterine mass / body mass. The uterus and bilateral fallopian tubes of the rats were sliced.

[0077] 2.3.4 Statistical analysis

[0078] Three researchers randomly selected different groups of samples for independent operation and took the average value. SPSS 17.0 statistical analysis software was used for data processing. All data were analyzed by express.

[0079] 2.4 Results

[0080] 2.4.1 Visual observation and scoring

[0081] It can be seen that there is no obvious adhesion in the pelvic and abdominal cavity and uterus of the rats in the blank group and the sham operation group. The size and shape of the fallopian tubes are normal, the texture is soft, shiny, the wall of the tube is smooth, and there is no thickening, water accumulation and other lesions; in the model group, the fallopian tube tissue is severely congested, the lumen is thickened, the shape is distorted, and it is closely adhered to the pelvic and abdominal cavity and adjacent organs and tissues and difficult to separate. Most of them can be seen to have fluid accumulation, uterine congestion and edema, the toughness and elasticity of the uterine wall are reduced, and it is widely adhered to the surrounding tissues, and the mobility is poor; the lumen of the fallopian tubes of the rats in the low-dose group is slightly thickened, and the tissue is less adherent The fallopian tubes of the rats in the medium-dose group were slightly thickened, with occasional subtle tissue adhesions and a small amount of fluid accumulation, no uterine edema, and the toughness and elasticity of the uterine wall tended to normal, without fluid accumulation, and normal activity. The fallopian tubes of the rats in the high-dose group were not thickened, with very little tissue adhesion, no fluid accumulation, no uterine edema, and the toughness and elasticity of the uterine wall tended to normal, without fluid accumulation, and normal activity. The fallopian tubes of the rats in the Penyanjing Granule group were roughly similar to those in the medium-dose group.

[0082] 2.4.2 Pathological evaluation

[0083] The uterine tissue was processed and evaluated by HE staining. The weighed uterus was fixed in 4% paraformaldehyde solution for 72 hours, and then processed for paraffin pathological sections to obtain clear sections. The intrauterine adhesion, epithelial degeneration and necrosis, and chronic inflammatory infiltration were observed under an upright microscope and scored from 0 to 3 points according to the degree of lesions, and the average value was taken. The pathological observation index and scoring standard were as follows: intrauterine adhesion occlusion: no lesion was scored 0 points; lesions <1 / 3 were scored 1 point; lesions 1 / 3 to 2 / 3 were scored 2 points; lesions more than 2 / 3 were scored 3 points. The cavity wall structure lesions: normal structure of each layer was scored 0 points; disappearance of the glandular structure of the mucosal lamina propria was scored 1 point; unclear boundary between the muscle layer and the mucosal layer was scored 2 points; unclear layered structure was scored 3 points. Epithelial cell degeneration and necrosis: single-layer columnar epithelium is scored as 0 points; epithelial cells are flattened or shed <1 / 3 is scored as 1 point; epithelial cells are flattened or shed 1 / 3 to 2 / 3 of the lesions are scored as 2 points; full-thickness epithelial cell degeneration and necrosis is scored as 3 points. Chronic inflammatory cell infiltration: no chronic inflammatory cell infiltration is scored as 0 points; a few scattered or focal infiltrations and only in the mucosal lamina propria are scored as 1 point; scattered or focal infiltrations but deep into the muscular layer are scored as 2 points; most scattered or laminar infiltrations and involving the entire layer are scored as 3 points. Congestion and edema are expressed as swelling inhibition rate. The results are shown in Table 1. The scores of each item in Table 1 are the sum of the average scores of the three experimenters for the item.

[0084] Swelling degree = model uterine mass m-uterine mass after administration m, inhibition rate = swelling degree / uterine mass after administration m*100%

[0085] Table 1 Effect of Jinyin Yimu Ning mixture on uterine pathological changes (scoring results and swelling) in rats with pelvic inflammatory disease model

[0086]

[0087]

[0088] From Table 1, it can be seen that each dose group of Jinyin Yimu Ning mixture can reduce the trend of uterine inflammation swelling in the rat model of chronic pelvic inflammatory disease. The effect of the medium dose group is equivalent to that of the Penyanjing group, while the high dose group is better than the Penyanjing group; both can improve the degree of endometrial lesions in the rat model of chronic pelvic inflammatory disease.

[0089] 2.4.3 Effects on the expression of TGF-β1, Smad2, and Smad3 proteins in model rats

[0090] The color digital medical image analysis system was used to evaluate the expression of TGF-β1, Smad2 and Smad3 proteins in the fallopian tube. The results are shown in Table 2.

[0091] Table 2 Effects of Jinyin Yimu Ning mixture on the expression of TGF-β1, Smad2 and Smad3 proteins (n=10, )

[0092]

[0093] Note: Compared with the blank group, #P<0.05, ##P<0.01. Compared with the model group, Compared with the Penyanjing group, ●P<0.05, ●●P<0.01.

[0094] Compared with the blank group and the sham operation group, there was no difference in the expression of TGF-β1, Smad2, and Smad3 proteins (P>0.05). Compared with the blank and sham operation groups, the expression of TGF-β1, Smad2, and Smad3 in rats in the model group and the Penyanjing granule group at each dose group was significantly different (P<0.05, P<0.01). Compared with the model group, the expression of TGF-β1, Smad2, and Smad3 in rats in each dose group and the Penyanjing granule group was significantly different (P<0.05, P<0.01). It was confirmed that Jinyin Yimu Ning mixture had an inhibitory effect on the expression of TGF-β1, Smad2, and Smad3 in rats, among which the high dose had the most obvious therapeutic effect. It may inhibit the conduction of the TGF-β1 / Smads signaling pathway by inhibiting the phosphorylation of Smad protein.

[0095] 2.4.4 The effects on IL-2, IL-6, TNF-α, and IL-10 in rats with pelvic inflammatory disease model are shown in Table 3.

[0096] Table 3 Effects of Jinyin Yimu Ning mixture on IL-2, IL-6, TNF-α, and IL-10 (n=10, pg / mL)

[0097]

[0098] Note: Compared with the blank group, #P<0.05, ##P<0.01. Compared with the model group, P<0.01. Compared with the Penyanjing group, ●P<0.05, ●●P<0.01.

[0099] There was no difference in IL-2, IL-6, TNF-α, and IL-10 between the blank group and the sham operation group (P>0.05). Compared with the blank and sham operation groups, there were significant differences in IL-2, IL-6, TNF-α, and IL-10 in the model group and the Penyanjing granule group at each dose group (P<0.05, P<0.01). Compared with the model group, there were significant differences in IL-2, IL-6, TNF-α, and IL-10 in the rats of each dose group and the Penyanjing granule group (P<0.05, P<0.01). IL-6 and TNF-α are inflammatory factors, and IL-2 and IL-10 are immunoregulatory factors, indicating that each administration group can effectively improve the inflammation of rats and improve the immunoregulatory ability.

[0100] 2.4.5 Effects on reproductive organ indexes of model rats

[0101] After the rats were weighed, the uterus and oviduct (nest) were removed, and the uterus and oviduct (nest) were weighed after being rinsed with saline. The reproductive organ index = reproductive organ weight / rat body weight organ index × 100%. See Table 4.

[0102] Table 4 Effects of Jinyin Yimu Ning mixture on reproductive organ indexes (n=15, )

[0103]

[0104] Note: Compared with the blank group, #P<0.05, ##P<0.01. Compared with the model group,

[0105] Compared with the Penyanjing group, ●P<0.05, ●●P<0.01.

[0106] Compared with the blank group and the sham operation group, the uterus and fallopian tube (nest) indexes of the rats in the other groups were increased; compared with the model group, the uterus and fallopian tube (nest) indexes of the low, medium, high dose groups and the Penyanjing granule group were reduced (P<0.05); compared with the Penyanjing granule group, the uterus and fallopian tube (nest) indexes of the rats in the medium and high dose groups were not significantly different (P>0.05), but their data were better than those of the Penyanjing granule. It is confirmed that the Jinyin Yimu Ning mixture can better protect the reproductive organs of the model rats and relieve the edema of the reproductive organs of the model rats.

[0107] 3. Effect of Jinyin Yimu Ning mixture on promoting blood circulation and removing blood stasis in rats with pelvic inflammatory disease model

[0108] 3.1 Materials

[0109] Epinephrine hydrochloride injection (1 ml × 10 vials, Shanghai Quanyu Biotechnology Animal Pharmaceutical Co., Ltd., batch number 20231008), heparin sodium (Hefei Bomei Biotechnology Co., Ltd., ≥180U / mg, batch number SJ223801).

[0110] 1.2 Important instruments: Medik fully automatic blood rheometer.

[0111] 3.2 Experimental methods

[0112] 3.2.1 Preparation of acute blood stasis rat model

[0113] 60 rats were randomly selected and given 10mL / kg ig once a day for 15 consecutive days. After the last dose, 0.2mL / kg of epinephrine hydrochloride was injected subcutaneously. After an interval of 4 hours, the same amount of epinephrine hydrochloride was injected again. The rats were immersed in ice water for 5 minutes at an interval of 2 hours. After treatment, they were fasted for 12 hours. The living conditions of the rats were observed the next morning, and rats that met the acute blood stasis model were selected for the experiment.

[0114] 3.2.2 Experimental methods

[0115] There were 6 groups in the experiment: blank group (10 rats were not injected with epinephrine hydrochloride or ice water bath), model control group, Penyanjing granule group (13.95 g / kg·d -1 ), low-dose group of Jinyin Yimu Ning mixture (3.24 g / kg·d -1 ), medium dose group (6.48 g / kg·d -1 ), high-dose group (12.96 g / kg·d -1 ) (Calculated based on a 60kg adult taking 100mL per day).

[0116] The next morning, the rats in each group with successful modeling were anesthetized with 10% chloral hydrate solution at 5 mL / kg intraperitoneally (fasted for 12 hours before anesthesia), blood was collected from the abdominal aorta, anticoagulated with heparin sodium, and whole blood viscosity, plasma viscosity, and hematocrit were measured.

[0117] 3.2.3 Statistical analysis

[0118] Three researchers randomly selected different groups of samples for independent operation and took the average value. SPSS 17.0 statistical analysis software was used for data processing. All data were analyzed by express.

[0119] 3.2.4. The results are shown in Table 5.

[0120] Table 5 Effect of Jinyin Yimu Ning mixture on blood rheology in rats with acute blood stasis model (n=10, )

[0121]

[0122]

[0123] Note: Compared with the blank group, #P<0.05, ##P<0.01. Compared with the model group, P<0.01. Compared with the Penyanjing group, ●P<0.05, ●●P<0.01.

[0124] As can be seen from Table 5, compared with the blank group, the whole blood viscosity (high shear, medium shear, low shear), plasma viscosity, and hematocrit of the model group were significantly increased, indicating that the model was successful. Compared with the model group, the Penyanjing granule group, the low-dose group, the medium-dose group, and the high-dose group of Jinyin Yinmu Ning mixture were able to significantly reduce the whole blood viscosity, plasma viscosity, and hematocrit, proving that Jinyin Yinmu Ning mixture has a good blood circulation and stasis-removing effect on blood stasis model rats. There was no significant difference between the medium-dose group and the Penyanjing granule group (P>0.05), and the high-dose group had a better therapeutic effect than the Penyanjing granule group.

[0125] It can be seen that the Chinese medicine preparation (Jinyin Yimu Ning mixture) for treating gynecological pelvic inflammatory disease of the present invention can improve the degree of endometrial lesions in the rat model of chronic pelvic inflammatory disease, can better protect the reproductive organs of the model rats, relieve the edema of the reproductive organs of the model rats, and has the effect of promoting blood circulation and removing blood stasis. Its therapeutic effect is better than that of Penyanjing granules, especially the high-dose group has more obvious effects.

Claims

1. A Chinese medicine preparation for treating gynecological pelvic inflammatory disease, characterized in that It is prepared from the following components in parts by weight: 10-16 parts of Smilax glabra, 5-7 parts of Ilex tomentosa, 5-7 parts of Honeysuckle vine, 5-8 parts of Taraxacum, 5-7 parts of Plantain, 5-7 parts of Leonurus japonicus, 5-7 parts of Fructus Smilacis Glabrae, 7-11 parts of Red Peony Root, 5-8 parts of Ligusticum chuanxiong, 5.5-6.5 parts of Cyperus rotundus with vinegar, 7-10 parts of Cherry Blossom Root, 6-10 parts of Cibotium barometz, and 11-15 parts of Prunus mume.

2. The Chinese medicine preparation for treating gynecological pelvic inflammatory disease according to claim 1, characterized in that It is prepared from the following components in parts by weight: 13 parts of Rhizoma Smilacis Glabrae, 6 parts of Ilex Tomentosa, 6 parts of Caulis Honeysuckle, 6 parts of Herba Taraxaci, 6 parts of Herba Plantaine, 6 parts of Herba Leonuri, 6 parts of Fructus Liquidambaridis, 9 parts of Radix Paeoniae Rubra, 6 parts of Rhizoma Chuanxiong with wine, 6 parts of Rhizoma Cyperi with vinegar, 9 parts of Radix Chrysanthemi Laevigatae, 8 parts of Cibotium Caninae, and 13 parts of Prunus Armeniacae.

3. The Chinese medicine preparation for treating gynecological pelvic inflammatory disease according to claim 1, characterized in that The dosage form of the traditional Chinese medicine preparation is one of oral liquid, tablet, granule and capsule.

4. A method for preparing a Chinese medicine preparation for treating gynecological pelvic inflammatory disease according to any one of claims 1 to 3, characterized in that The following steps are involved: S1 Weigh each Chinese medicine component in proportion and mix them together, add 4 to 8 times of drinking water to soak for 30 to 50 minutes, heat to 100°C and keep it slightly boiling for 30 to 60 minutes; S2 filters the cooked medicinal liquid in S1 to obtain the filtrate for later use; adds 4 to 6 times of drinking water to the filtered medicinal residue, and repeats the above heating and filtering operations 1 to 2 times; S3 combines several filtrates, heats them in a concentrator and concentrates them into a concentrated liquid or thick paste, and then sterilizes them to prepare the desired dosage form.

5. The method for preparing the Chinese medicine preparation for treating gynecological pelvic inflammatory disease according to claim 4, characterized in that When the dosage form to be prepared is an oral liquid, the filtrate needs to be heated and concentrated in a concentrator, and an appropriate amount of pharmaceutical excipients is added, stirred evenly, and packaged according to the required specifications.

6. The method for preparing the Chinese medicine preparation for treating gynecological pelvic inflammatory disease according to claim 5, characterized in that The pharmaceutical excipient is sodium benzoate, and the added amount of the sodium benzoate is 0.1-0.2% of the mass of the concentrated solution.

Citation Information

Patent Citations

  • Preparation method of Penyanjing oral solution

    CN105168379A

  • Composition for treating gynecological disease, agent containing composition and preparation method of composition

    CN106511500A

  • Pelvic inflammation clearing granule for treating gynecological diseases and method for preparing pelvic inflammation clearing granule

    CN109453153A